215 related articles for article (PubMed ID: 26531233)
41. Combined pharmacophore, virtual screening and molecular dynamics studies to identify Bruton's tyrosine kinase inhibitors.
Sakthivel S; Habeeb SKM
J Biomol Struct Dyn; 2018 Dec; 36(16):4320-4337. PubMed ID: 29293382
[TBL] [Abstract][Full Text] [Related]
42. Next-generation Bruton's Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives.
Das D; Wang J; Hong J
Curr Top Med Chem; 2022; 22(20):1674-1691. PubMed ID: 35927919
[TBL] [Abstract][Full Text] [Related]
43. Label-Free Bottom-Up Proteomic Workflow for Simultaneously Assessing the Target Specificity of Covalent Drug Candidates and Their Off-Target Reactivity to Selected Proteins.
Yang Y; Shu YZ; Humphreys WG
Chem Res Toxicol; 2016 Jan; 29(1):109-16. PubMed ID: 26675335
[TBL] [Abstract][Full Text] [Related]
44. Discovery of novel Bruton's tyrosine kinase inhibitors using a hybrid protocol of virtual screening approaches based on SVM model, pharmacophore and molecular docking.
Wan HL; Wang ZR; Li LL; Cheng C; Ji P; Liu JJ; Zhang H; Zou J; Yang SY
Chem Biol Drug Des; 2012 Sep; 80(3):366-73. PubMed ID: 22594639
[TBL] [Abstract][Full Text] [Related]
45. Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitors.
Qiu H; Liu-Bujalski L; Caldwell RD; Viacava Follis A; Gardberg A; Goutopoulos A; Grenningloh R; Head J; Johnson T; Jones CCV; Jones R; Mochalkin I; Morandi F; Neagu C; Potnick J; Sherer B
Bioorg Med Chem Lett; 2018 Nov; 28(20):3307-3311. PubMed ID: 30243592
[TBL] [Abstract][Full Text] [Related]
46. Discovery of Tricyclic Pyranochromenone as Novel Bruton's Tyrosine Kinase Inhibitors with in Vivo Antirheumatic Activity.
Cho H; Lee E; Kwon HA; Seul L; Jeon HJ; Yu JH; Ryu JH; Jeon R
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33113810
[TBL] [Abstract][Full Text] [Related]
47. Metabolically Labile Fumarate Esters Impart Kinetic Selectivity to Irreversible Inhibitors.
Zaro BW; Whitby LR; Lum KM; Cravatt BF
J Am Chem Soc; 2016 Dec; 138(49):15841-15844. PubMed ID: 27960302
[TBL] [Abstract][Full Text] [Related]
48. Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers.
Watterson SH; De Lucca GV; Shi Q; Langevine CM; Liu Q; Batt DG; Beaudoin Bertrand M; Gong H; Dai J; Yip S; Li P; Sun D; Wu DR; Wang C; Zhang Y; Traeger SC; Pattoli MA; Skala S; Cheng L; Obermeier MT; Vickery R; Discenza LN; D'Arienzo CJ; Zhang Y; Heimrich E; Gillooly KM; Taylor TL; Pulicicchio C; McIntyre KW; Galella MA; Tebben AJ; Muckelbauer JK; Chang C; Rampulla R; Mathur A; Salter-Cid L; Barrish JC; Carter PH; Fura A; Burke JR; Tino JA
J Med Chem; 2016 Oct; 59(19):9173-9200. PubMed ID: 27583770
[TBL] [Abstract][Full Text] [Related]
49. Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
Caldwell R; Liu-Bujalski L; Qiu H; Mochalkin I; Jones R; Neagu C; Goutopoulos A; Grenningloh R; Johnson T; Sherer B; Gardberg A; Follis AV; Morandi F; Head J
Bioorg Med Chem Lett; 2018 Nov; 28(21):3419-3424. PubMed ID: 30290988
[TBL] [Abstract][Full Text] [Related]
50. 'Turn On/Off' fluorescence probe for the screening of unactivated Bruton's tyrosine kinase.
Kawahata W; Asami T; Fujii I; Sawa M
Bioorg Med Chem Lett; 2015; 25(10):2141-5. PubMed ID: 25843639
[TBL] [Abstract][Full Text] [Related]
51. Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
Xue Y; Song P; Song Z; Wang A; Tong L; Geng M; Ding J; Liu Q; Sun L; Xie H; Zhang A
J Med Chem; 2018 May; 61(10):4608-4627. PubMed ID: 29715023
[TBL] [Abstract][Full Text] [Related]
52. Mitigation of reactive metabolite formation for a series of 3-amino-2-pyridone inhibitors of Bruton's tyrosine kinase (BTK).
Lou Y; Lopez F; Jiang Y; Han X; Brotherton C; Billedeau R; Gabriel S; Gleason S; Goldstein DM; Hilgenkamp R; Kocer B; Orzechowski L; Tan J; Wovkulich P; Wen B; Fry D; Di Lello P; Chen L; Zhang FJ; Fretland J; Nangia A; Yang T; Owens TD
Bioorg Med Chem Lett; 2017 Feb; 27(3):632-635. PubMed ID: 28025004
[TBL] [Abstract][Full Text] [Related]
53. Discovery of 3-morpholino-imidazole[1,5-a]pyrazine BTK inhibitors for rheumatoid arthritis.
Boga SB; Alhassan AB; Liu J; Guiadeen D; Krikorian A; Gao X; Wang J; Yu Y; Anand R; Liu S; Yang C; Wu H; Cai J; Zhu H; Desai J; Maloney K; Gao YD; Fischmann TO; Presland J; Mansueto M; Xu Z; Leccese E; Knemeyer I; Garlisi CG; Bays N; Stivers P; Brandish PE; Hicks A; Cooper A; Kim RM; Kozlowski JA
Bioorg Med Chem Lett; 2017 Aug; 27(16):3939-3943. PubMed ID: 28720503
[TBL] [Abstract][Full Text] [Related]
54. Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
Zhang C; Pei H; He J; Zhu J; Li W; Niu T; Xiang M; Chen L
Eur J Med Chem; 2019 May; 169():121-143. PubMed ID: 30875504
[TBL] [Abstract][Full Text] [Related]
55. New affinity probe targeting VEGF receptors for kinase inhibitor selectivity profiling by chemical proteomics.
Ku X; Heinzlmeir S; Helm D; Médard G; Kuster B
J Proteome Res; 2014 May; 13(5):2445-52. PubMed ID: 24712744
[TBL] [Abstract][Full Text] [Related]
56. Clinical potential of targeting Bruton's tyrosine kinase.
Uckun FM
Int Rev Immunol; 2008; 27(1-2):43-69. PubMed ID: 18300055
[TBL] [Abstract][Full Text] [Related]
57. Design, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors.
Yang M; Jiang H; Yang Z; Liu X; Sun H; Hao M; Hu J; Chen X; Jin J; Wang X
Eur J Med Chem; 2022 Nov; 241():114611. PubMed ID: 35939993
[TBL] [Abstract][Full Text] [Related]
58. Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834.
Young WB; Barbosa J; Blomgren P; Bremer MC; Crawford JJ; Dambach D; Gallion S; Hymowitz SG; Kropf JE; Lee SH; Liu L; Lubach JW; Macaluso J; Maciejewski P; Maurer B; Mitchell SA; Ortwine DF; Di Paolo J; Reif K; Scheerens H; Schmitt A; Sowell CG; Wang X; Wong H; Xiong JM; Xu J; Zhao Z; Currie KS
Bioorg Med Chem Lett; 2015 Mar; 25(6):1333-7. PubMed ID: 25701252
[TBL] [Abstract][Full Text] [Related]
59. Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.
MacPartlin M; Smith AM; Druker BJ; Honigberg LA; Deininger MW
Leukemia; 2008 Jul; 22(7):1354-60. PubMed ID: 18548107
[TBL] [Abstract][Full Text] [Related]
60. Molecular modelling studies on cinnoline-based BTK inhibitors using docking and structure-based 3D-QSAR.
Li R; Du Y; Shen J
SAR QSAR Environ Res; 2018 Nov; 29(11):847-873. PubMed ID: 30280589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
